Recent Publications

Research Papers

(Peer-reviewed)

44. G. Zhang#, S. Li#, F. Wang#, A.C. Jones#, A.F.G. Goldberg, B. Lin, S. Virgil, B.M. Stoltz, R.J. Deshaies#, and T.-F. Chou. A Covalent p97/VCP ATPase Inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells. Eur. J. Med. Chem., 2021, doi:10.1016/j.ejmech.2020.113148. # These authors contributed equally.

2020:

43. F. Wang, D.R. Moen, C. Sauni, S. Kan, S. Li, S.Q. Le, B. Lomenick, X. Zhang, S. Ekins, S. Singamsetty, J. Wood, P.I. Dickson, and T.-F. Chou. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice. Mol Pharm. 2020, doi: 10.1021/acs.molpharmaceut.0c00831.

42. F. Wang, S. Li, T. Gan, G.M. Stott, A. Flint, and T.-F. Chou. Allosteric p97 inhibitors can overcome resistance to ATP-competitive p97 inhibitors for potential anti-cancer therapy. ChemMedChem, 2020, 15(8): 685-694.

2018:

41. M.G. LaPorte, J.C. Burnett, R. Colombo, S.L. Bulfer, C. Alverez, T.-F. Chou, R.J. Neitz, N. Green, W.J. Moore, Z. Yue, S. Li, M.R. Arkin, P. Wipf, D.M. Huryn. Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97. ACS Med. Chem. Lett. 2018, 9(11):1075-1081.

40. J. Li, Y. Zhang, B. Da Silva Sil Dos Santos, F. Wang, Y. Ma, C. Perez, Y. Yang, J. Peng, S.M. Cohen, T.-F. Chou, S.T. Hilton, and R.J. Deshaies. Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11. Cell Chem. Biol. 2018, pii: S2451- 9456(18)30264-2.

39. V. Sanghez, M. Chen, S. Li, T.-F. Chou, M. Iacovino, H.J. Lin, J.L. Lasky, and E.H. Panosyan. Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma. Anticancer Res., 2018, 38, 2627-2634.

2017:

38. M.A. Nakasone, T.A. Lewis, O. Walker, A. Thakur, W. Mansour, C.A. Castañeda, J.L. Goeckeler-Fried, F. Parlati, T.-F. Chou, O. Hayat, D. Zhang, C.M. Camara, S.M. Bonn, U.K. Nowicka, S. Krueger, M.H. Glickman, J.L. Brodsky, R.J. Deshaies, and D. Fushman Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway. Structure. 2017, 25,1839-1855.

37. V. Sanghez, A. Luzzi, D. Clarke, D. Kee, S. Buder, D. Rux, M. Osawa, J. Madrenas, T.-F. Chou, M. Kyba, M. Iacovino. Notch activation is required for downregulation of HoxA3-dependent endothelial cell phenotype during blood formation. PLoS One, 2017, 12, e0186818.

36. C. Perez, J. Li, F. Parlati, M. Rouffet, Y. Ma, H.J. Zhou, A.L. Mackinnon, T.-F. Chou, R.J. Deshaies, and S.M. Cohen, Correction to Discovery of an Inhibitor of the Proteasome Subunit Rpn11. J. Med. Chem., 2017; 60(7):3217.

35. P. Bastola, F. Wang, M.A. Schaich, T. Gan, B.E. Freudenthal, T.-F. Chou, and J. Chien, Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. Cell Death Discov., 2017, 60(7):3217.

34. R. Shah #, T.-F. Chou #, K.M. Maize, A. Strom, B.C. Finzel, and C.R. Wanger. Inhibition by Divalent Metal Ions of Human Histidine Triad Nucleotide Binding Protein1 (hHint1), a Regulator of Opioid Analgesia and Neuropathic Pain. Biochem. Biophys. Res. Commun., 2017, 491,760-766. # These authors contributed equally.

33. Y.J. Lee, T.-F. Chou, S.K. Pittman, and C.C. Weihl. Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA domain Ubiquitination. Cell Rep., 2017, 19,188-202

32. A. Segura-Cabrera, R. Tripathi, X. Zhang, L. Gui, T.-F. Chou, and K. Komurov. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase. Sci. Rep. 2017, 7,44912

31. C. Perez, J. Li, F. Parlati, M. Rouffet, Y. Ma, A.L. Mackinnon, T.-F. Chou, R.J. Deshaies, and S.M. Cohen. Discovery of an Inhibitor of the Proteasome Subunit Rpn11. J. Med. Chem. 2017, 60, 1343-1361.

2016:

30. S.L. Bulfer, T.-F. Chou, M.R. Arkin. p97 disease mutations modulate nucleotide-induced conformation to alter protein-protein interactions. ACS Chem Biol. 2016, 11, 2112-2116.

29. L. Gui, X. Zhang, K. Li, K. Frankowski, S. Li, D. Wong, D.R. Moen, P.R. Porubsky, H.J. Lin, F.J. Schoene, T.-F. Chou. Evaluating p97 Inhibitor Analogues for Potency against p97-p37 and p97-Npl4-Ufd1 Complexes. ChemMedChem, 2016, 11, 953-957.

2015:

28. M. Liu, L. Lin, T. Gebremariam, G. Luo, C. D. Skory, S. W. French, T.-F, Chou, J.E. Jr. Edwards, and A.S. Ibrahim. Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine. PLoS Pathog. 2015, 11, e1004842.

27. N.U. Jerath, C.D. Crockett, S.A. Moore, M.E. Shy, C.C. Weihl, T.-F. Chou, M.A. Gonzalez, S. Zuckner, and A. Swenson. Rare Manifestation of a c.290 C>T, p.Gly97Glu VCP Mutation. Case Rep Genet. 2015; 2015:239167.

26. X. Zhang, L. Gui, X. Zhang, S. L. Bulfer, V. Sanghez, D. Wong, Y.J. Lee, L. Lehmann, J.S. Lee, P.-Y. Shih, H.J. Lin, M. Iacovino, C.C. Weihl, M.R. Arkin, T. Wang, T.-F. Chou. Altered cofactor regulation with disease associated p97/VCP mutations. Proc. Natl. Acad. Sci. USA, 2015, 112, E1705-1714.

25. C.C. Weihl, R.H. Baloh, Y. Lee, T.-F. Chou, S.K. Pittman, G. Lopate, P. Allred, J. Jockel-Balsarotti, A. Pestronk, and M.B. Harms. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord., 2015 Apr;25(4):289-296.

24. C. Fang, L. Gui, X. Zhang, D.R. Moen, K. Li, K.J. Frankowski, H.J. Lin, F.J. Schoene, and T.-F. Chou. Evaluating p97 inhibitor analogues for their domain-selectivity and potency against the p97-p47 complex. ChemMedChem, 2015, 10, 52-56.

2014:

23. M. Kato, T.-F. Chou, C.Z. Yu, J. Demodena, and P.W. Sternberg. LINKIN, a new transmembrane protein necessary for cell adhesion. eLife. 2014, 3, e04449.

22. A. Sapir, A. Tsur, T. Koorman, K. Ching, A. Bardenheier, L. Podolsky, U. Bening-Abu-Shach, M. Boxem, T.-F. Chou, L. Broday, and P.W. Sternberg. Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging. Proc. Natl. Acad. Sci. USA. 2014, 111, E3880-3889.

21. M.A. Gonzalez, S. Feely, F. Speziani, A. Strickland, M. Danzi, C. Bacon, Y. Lee, T.-F. Chou, S.H. Blanton, C.C. Weihl, S. Zuchner, and M. Shy. A Novel Mutation in VCP Causes Charcot-Marie-Tooth Type 2 Disease. Brain, 2014, 137(11), 2897-2902.

20. T.-F. Chou*, S. L. Bulfer, C.C. Weihl, K. Li, L.G. Lis, M.A. Walters, F.J. Schoenen, H.J. Lin, R.J. Deshaies, and M.R. Arkin. Specific Inhibition of p97/VCP ATPase and Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase domains. J. Mol. Biol. 2014, 426, 2886-2899. *Corresponding author

2013:

19. X. Zhou, T.-F. Chou, B.E. Aubol, C.J. Park, R. Wolfenden, J. Adams, and C.R. Wagner. Kinetic Mechanism of Human Histidine Triad Nucleotide Binding Protein 1 (Hint1). Biochemistry, 2013, 52, 3588-3600.

18. T.-F. Chou*, K. Li, K. Frankowski, F.J. Schoenen, and R.J. Deshaies*. Structure- Activity Relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013, 8,297-312. *Co-corresponding authors

2011:

17. S. Bardaweel, B. Ghosh, T.-F. Chou, M.J. Sadowsky, and C.R. Wagner. E. coli histidine triad nucleotide binding protein 1 (ecHinT) is a catalytic regulator of D-alanine dehydrogenase (DadA) activity in vivo. PLoS One. 2011, 6, e20897.

16. T.-F. Chou*, and R. J. Deshaies*. Development of p97 AAA ATPase inhibitors. Autophagy. 2011, 7, 1091-1092. *Co-corresponding authors

15. G. Birkus, N. Kutty, C.R. Frey, R. Shribata, T.-F. Chou, C.R. Wagner, M. McDermott, and T. Cihlar. Role of cathepsin A and lysosomes in the intracellular activation of novel anti-papillomavirus agent GS-9191. Antimicrob. Agents Chemother. 2011, 55, 2166 - 2173.

14. T.-F. Chou*, S. J. Brown, D. Minond, B.E. Nordin, K. Li, A.C. Jones, P. Chase, P. R. Porubsky, B.M. Stoltz, F.J. Schoenen, M.P. Patricelli, P. Hodder, H. Rosen, and R. J Deshaies*. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc. Natl. Acad. Sci. USA. 2011, 108, 4834 - 4839. *Co-corresponding authors

13. T.-F. Chou*, and R.J. Deshaies*. Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J. Biol. Chem. 2011, 286, 16546 - 16554. *Co-corresponding authors

2010:

12. S. Bardaweel, J. Pace, T.-F. Chou, V. Cody, and C.R. Wagner. Probing the impact of the echinT c-terminal domain on structure and catalysis. J. Mol. Biol. 2010, 404, 627 - 638.

2009:

11. J. Cheng, X. Zhou, T.-F. Chou, B. Ghosh, B. Liu, and C.R. Wagner. Identification of the amino acid-AZT-phosphoramidase by affinity T7 phage display selection. Bioorg. Med. Chem. Lett. 2009, 19, 6379 - 6381.

2008:

10. T.-F. Chou, C. So, B.R. White, J.C.T. Carlson, M. Sarikaya, and C.R. Wagner Enzyme nanorings. ACS Nano 2008, 2, 2519 - 2525.

9. P. Ghosh, J. Chen, T.-F. Chou, Y. Jia, S. Avdulov, P. B. Bitterman, V. A. Polunovsky, and C.R. Wagner. Expression, purification and characterization of recombinant mouse initiation factor eIF-4E as a dihydrofolate reductase (DHFR) fusion protein. Protein Expr. Purif., 2008, 60, 132 - 139.

2007:

8. T.-F. Chou, Y. Y. Sham, and C. R. Wagner. The Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate specificity. Biochemistry, 2007, 46, 13074 - 13079.

7. T.-F. Chou, J. Cheng, I. B. Tikh, and C. R. Wagner. Evidence that human histidine triad nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad (HIT) superfamily. J. Mol. Biol.2007, 373, 978 - 989.

6. T.-F. Chou, I. B. Tikh, B.A.C. Horta, B. Ghosh, R.B. de Alencastro, and C. R. Wagner. Engineered monomeric human histidine triad nucleotide binding protein 1 hydrolyzes fluorogenic acyl -adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate. J. Biol. Chem. 2007, 282, 15137 - 15147.

5. T.-F. Chou, J. Baraniak, R. Kaczmarek, X. Zhou, J. Cheng, B. Ghosh, and C. R. Wagner. Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and E. coli histidine triad nucleotide binding proteins (Hint1). Mol. Pharma. 2007, 4, 208 - 217.

4. T.-F. Chou and C. R. Wagner. Lysyl-tRNA synthetase generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins (Hints). J. Biol. Chem. 2007, 282, 4719 - 4727.

2006:

3. J. C. T. Carlson, S. S. Jena, F. Flenniken, T.-F. Chou, R. A. Siegel, and C. R. Wagner. Chemically controlled self-assembly of protein nanorings. J. Am. Chem. Soc. 2006, 128, 7630 - 7638.

2005:

2. T.-F. Chou, Bieganowski, P., Shilinski, K., Cheng, J., Brenner, C., and Wagner, C. R. 31P-NMR and genetic analysis establish hinT as the only Escherichia coli purine nucleoside phosphoramidase and as essential for growth under high salt conditions. J. Biol. Chem. 2005, 280, 15356 - 15361.

2004:

1. J. Kim, T.-F. Chou, Griesgraber, G. W., and Wagner, C. R. Direct measurement of nucleoside monophosphate delivery from a phosphoramidate pronucleotide by stable isotope labeling and LCESI- MS/MS. Mol. Pharm. 2004, 1, 102 - 111.